



Corporate Presentation
June 2026

 **entrada**
THERAPEUTICS

Disclaimer



This presentation has been prepared by Entrada Therapeutics, Inc. (“Entrada”) and shall not constitute an offer to sell or a solicitation of an offer to buy securities or an invitation or inducement to engage in investment activity nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of such securities under the securities law of any such jurisdiction. Before you invest in any securities of Entrada, you should read any documents Entrada has filed with the SEC for more complete information about Entrada and the offering. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov.

This presentation contains express and implied forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding Entrada’s strategy, future operations, prospects and plans, objectives of management, the validation, differentiation and superiority of Entrada’s approach and EEV platform and its ability to provide a potential best-in-class outcomes in high unmet need diseases, expectations regarding Entrada’s Phase 1/2 MAD clinical study of ENTR-601-44, including the completion of the Cohort 1 open-label period by year-end 2026 and the reporting, translatability, and ability to achieve a clinically meaningful effect from additional metrics data, including 10-meter walk/run, stride velocity 95th centile, 4-stair climb, north star ambulatory, and performance upper limb, the translatability of dystrophin concentrations and exon skipping based on juvenile NHP data, expected continued benefit in muscle function in the open-label period of Cohort 1 and future Cohorts, the timing of competitive data from Cohort 2 by year-end 2026, with expected higher levels of plasma and muscle exposure (linear or better) and substantially higher dystrophin expression including the potential of double-digit dystrophin levels, increases in muscle function and continued functional response over time, the timing of data from Cohort 3 to follow, expected significantly increased exon skipping and dystrophin expression for Cohorts 2 and 3, expectations regarding the data from the clinical study of ENTR-601-44, including expected results such as higher dystrophin restoration and positive safety data, expectations regarding muscle regeneration, muscle stabilization, and greater strength in patients as measured by Time to Rise velocity, expectations regarding the connection between EEV-PMO uptake in satellite cells and muscle regeneration, speed and durability of functional improvement, expectations of lower risk of anti-drug antibody response and lower cost of goods from EEV-PMO conjugates, translatability of current data to de-risk Entrada’s DMD clinical portfolio, support dose escalations, and its ability to support U.S. Accelerated Approval, expectations regarding Entrada’s Phase 1/2 MAD clinical study of ENTR-601-45 and the timing of first-in-class data from Cohort 1 in mid-2026, expectations regarding ENTR-601-45 and its potential best-in-class clinical profile, expectations regarding regulatory filings in the EU for the planned Phase 1/2 MAD clinical study of ENTR-601-50, expectations regarding the global regulatory filings for the planned clinical study of ENTR-601-51, the ability to recruit for and complete global Phase 2 clinical studies of ENTR-601-44, ENTR-601-45, ENTR-601-50 and ENTR-601-51 and to obtain U.S. Accelerated Approval and/or full approval for each program, the ability of EEV therapies to provide a 25-50-fold improvement in endosomal escape and lower whole drug requirements compared to antibody-based therapies, the ability to continue to expand and develop additional therapeutic programs and modalities, including further exon skipping programs, the potential therapeutic benefits of Entrada’s EEV product candidates and the ability to advance therapeutic candidates in indications beyond neuromuscular disease, including but not limited to ocular disease, expectations regarding the timing of nomination of a second clinical candidate for inherited retinal disease in the second half of 2026, expectations regarding Entrada’s ENTR-801 program, including the potential for quarterly dosing, initiation of IND-enabling studies and Entrada sharing clinical strategies in 2026, expectations regarding Entrada’s next-generation exon skippers, including durable and significant access to skeletal and cardiac muscle, targeting of progenitor cells and flexibility to dose escalate and re-dose, the continued development and advancement of ENTR-601-44, -45, -50 and -51 for the potential treatment of DMD and ENTR-801 for the potential treatment of Usher syndrome type 2A and the partnered product candidate VX-670 for the potential treatment of DM1, expectations regarding the progress and success of Entrada’s collaboration with Vertex, including expected proceeds from program milestones plus royalties and completion of the MAD portion of the global Phase 1/2 study of the VX-670 program and results shared in the second half of 2026, the size of the DMD market opportunity in the U.S. and ex-US, and the sufficiency of Entrada’s cash resources into the third quarter of 2027, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Entrada may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the conduct of research activities and the initiation and completion of preclinical studies and clinical studies; uncertainties as to the availability and timing of results from preclinical and clinical studies; the timing of and Entrada’s ability to submit and obtain regulatory clearance and initiate clinical studies; whether results from preclinical studies or clinical studies will be predictive of the results of later preclinical studies and clinical studies or comparative performance against competing products or product candidates; whether Entrada’s cash resources will be sufficient to fund Entrada’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in Entrada’s filings with the SEC, including Entrada’s most recent Form 10-K and in subsequent filings Entrada may make with the SEC. In addition, the forward-looking statements included in this presentation represent Entrada’s views as of the date of this presentation. Entrada anticipates that subsequent events and developments will cause its views to change. However, while Entrada may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Entrada’s views as of any date subsequent to the date of this presentation.

2026 is a transformational year for Entrada



Entrada is a clinical-stage biopharma company developing proprietary genetic medicines to deliver best-in-class outcomes in high unmet need diseases

Deep pipeline with value inflection points in 2026

- **5 clinical-stage programs** in DMD and DM1
- **4 clinical data catalysts** in DMD and DM1 patients achieved or expected in 2026
- **2 development candidates** in inherited retinal diseases projected by year-end 2026

Differentiated programs in untapped markets

- **\$5 billion U.S. DMD market**, with limited competitive penetration; Untapped global markets
- **FDA Accelerated Approval strategy** to be supported by Phase 1/2 data from ex-U.S. DMD studies
- **Proprietary and differentiated** delivery and active moiety sequences in all candidate programs
- **Favorable safety data and early but compelling functional improvement results***
- **Best-in-class preclinical data** in all declared clinical and preclinical programs

Capitalized to realize value catalysts

- **Cash runway into Q3 2027**
- **Up to \$485 million in DM1 milestones**, plus royalties associated with Vertex partnership

Clinical inflection points for ENTR-601-44, ENTR-601-45 and VX-670 in 2026; ENTR-601-44 safety data fundamentally de-risks the neuromuscular portfolio

Rapidly Expanding DMD Clinical Franchise

ENTR-601-44

- Cohort 1 MAD complete; All patients transitioned to open-label dosing
- Cohort 2 dose escalation cleared to initiate at 12 mg/kg; Dosing ongoing
- Cohort 1 open-label and Cohort 2 MAD data expected by year-end 2026

ENTR-601-45

- Cohort 2 dose escalation cleared to initiate at 10 mg/kg; Enrollment ongoing
- Cohort 1 data expected mid-2026

ENTR-601-50 and ENTR-601-51

- Additional regulatory filings expected following a review of the data from the ongoing ENTR-601-44 and ENTR-601-45 DMD clinical studies

Vertex Advancing VX-670 for the Treatment of DM1

- Completed SAD portion of global Phase 1/2 study
- MAD evaluation of safety and efficacy is ongoing
- Vertex to share study results in H2 2026
- Partnership terms include up to \$485 million in milestones, plus royalties

Advancing Innovative Preclinical Pipeline

Inherited Retinal Diseases

- Nominated first ocular candidate, ENTR-801 for Usher syndrome type 2A
- Second program in lead optimization; Candidate declaration in H2 2026


Additional Discovery Efforts

- Expansion of neuromuscular and ocular franchises leveraging next-generation EEVs and oligonucleotides
- Evaluating a range of undisclosed diseases, targets and modalities

Advancing five fully owned programs and one partnered program

Phase 1/2 data from ex-U.S. DMD studies to support Accelerated Approval regulatory filings in the U.S.

Each target disease has a substantial patient population with a significant unmet medical need



Duchenne Muscular Dystrophy (DMD)

Entrada's DMD strategy is to de-risk a differentiated portfolio and commercially launch best-in-class drugs

Three strategic pillars: Differentiation, de-risking and best-in-class opportunities

Differentiated EEV™ Platform and Novel PMO Conjugates

- **Novel EEV and PMO** sequences
- **Best-in-class** non-clinical data translated into compelling safety and functional data
- Progenitor cell uptake supports **regenerative potential, speed and durability of functional improvement**
- **Lower whole drug exposure** supports lower risk of anti-drug antibody response and lower cost of goods

De-risked and Rapid Clinical Development

- Favorable ENTR-601-44 Phase 1 healthy volunteer safety profile
- Favorable ENTR-601-44 Phase 1/2 patient safety data for Cohort 1
- **Statistically significant improvement in functional benefit*** observed in ENTR-601-44 Cohort 1
- All neuromuscular programs **leverage the same EEV**
- **ENTR-601-44 Cohort 1 data de-risks the DMD franchise**

Potential for “Best-in-class” Commercial Opportunities

- Phase 1/2 data from ex-U.S. studies to support **U.S. Accelerated Approval****
- ENTR-601-44 Cohort 1 open-label and Cohort 2 MAD expected to deliver **competitive data** by year-end 2026
- **First-in-class clinical program in exon 45** projected to deliver Cohort 1 MAD data by mid-2026


Entrada is developing genetic medicines to correct the mechanism of disease and slow, halt or reverse progression

Entrada's Approach: Modulate RNA Splicing and Produce Functional Protein to Preserve and Rebuild Muscle

Individuals with Duchenne

Pre-mRNA

With exon deletion, protein program is miscoded



mRNA

Reading frame disrupted and body reads STOP!



No Translation

Protein

Resultant mRNA sequence stops the production of functional dystrophin protein



Entrada Approach

Pre-mRNA

Treatment enables skipping of exon



mRNA

Reading frame restored



Splice modulation


Translation

Protein

Functional dystrophin protein is translated and muscle membrane regains integrity




DMD Mutations and Tissues of Focus in the Entrada Portfolio



Heart



Diaphragm



Skeletal muscle



~8%

~9%

~4%

~15%

~35% = ~11,500 Patients*

Entrada addresses mutations which result in a lack of dystrophin, muscle breakdown, progressive disability and death


The portfolio covers ~35% of the total population totaling ~11,500 patients in the U.S. and EU*

Entrada's DMD franchise unlocks a potential \$5B U.S. market opportunity, with significant further upside ex-U.S.



Entrada's DMD franchise is positioned to address ~1/3 of all U.S. DMD patients, representing a potential ~\$5B annual market opportunity in the U.S. alone

~\$5 Billion Annual U.S. Commercial Opportunity*



- Few available treatment options and limited competitive penetration to date
- **~5,000 U.S. patients** addressable with exon skipping therapies 44, 45, 50 and 51**
- **~6,500 European patients** addressable with exon skipping therapies 44, 45, 50 and 51**
- Ex-U.S. market not factored into projections and represents further upside potential

ELEVATE-44-201

Cohort 1: Study Results Summary

Cohort 1 achieved the objective of demonstrating safety/tolerability; Importantly, Cohort 1 achieved functional benefit at the lowest dose with dystrophin levels expected to increase in Cohorts 2 and 3

- **Favorable safety and tolerability profile at 6 mg/kg; All AEs were mild to moderate**
 - No reported SAEs nor AEs leading to discontinuation
 - Renal markers within normal range and comparable to placebo
- **Functional benefit demonstrated at 6 mg/kg via Time to Rise and Time to Rise Velocity (TTR and TTRV) measures**
 - TTR is a secondary endpoint of the ELEVATE-44-201 study
 - Cohort 1 resulted in a statistically significant* impact on TTR and TTRV versus placebo
 - TTRV levels were several fold above MCID after only 3 doses (127 days, 6 weeks after the last dose administered)
 - Additional functional measurement data to be shared at the end of the open-label period (year-end 2026)
- **Mechanistic advantages support early functional benefit observations**
 - EEV-PMO uptake in satellite cells can lead to the proliferation, activation and asymmetric division which is the basis of muscle regeneration
 - Continued benefit in muscle function expected in the open-label period of Cohort 1 and future Cohorts
- **Updated PK modeling, based on recently received juvenile NHP data, supports higher dystrophin in Cohorts 2 and 3**
 - Due to lower plasma drug exposures, dystrophin levels in Cohort 1 were lower than predicted

Early functional benefit response is compelling and statistically significant

ELEVATE-44-201

Cohort 1: Trial Design and Treatment Population


ELEVATE-44-201 is designed to support U.S. Accelerated Approval and forms the basis of a global registrational program*

ENTR-601-44



ELEVATE-44-201 is a global, two-part, randomized, double-blind placebo-controlled Phase 1/2 study in ambulatory patients*

Primary objective: Safety and tolerability of ENTR-601-44
Secondary objectives: Evaluation of pharmacokinetics, exon skipping, dystrophin production and measures of function



	Placebo n=2	ENTR-601-44 6 mg/kg n=6
Age, mean	13.5	9.3
Body mass index, mean, kg/m ²	17.96	20.00
Age at disease onset, mean, years	1.0	2.2
Corticosteroid use, n (%)	2 (100%)	6 (100%)
Ambulatory, n (%)	2 (100%)	6 (100%)
Baseline dystrophin	4.6%	4.0%

- **Baseline dystrophin levels seen in Cohort 1 were the lowest levels observed in recent Exon 44 studies**
- **Higher levels of baseline dystrophin correlate to higher treatment responses and vice versa**

ELEVATE-44-201

Cohort 1: Safety Data

Safety was consistent and unremarkable at the 6 mg/kg dose

ELEVATE-44-201





Participants with ≥ 1 TEAE, n (%)	Placebo n=2	ENTR-601-44 6 mg/kg n=6
Any TEAE	2 (100%)	6 (100%)
TEAEs related to study drug	1 (50%)	5 (83%)
Serious TEAEs	0	0
TEAEs leading to study discontinuation	0	0
TEAEs leading to death	0	0

All TEAEs were mild to moderate

- Headache was the most common study drug-related TEAE, reported in 50% of the treatment group and 50% of the placebo group
- All events resolved
- **There were no serious TEAEs** and no study discontinuation due to any causes
- **No hypomagnesemia** or renal safety concerns were noted

A highly favorable safety profile supports a de-risking of DMD programs

Renal markers were within normal range and comparable to placebo



Renal marker results further de-risk current and future DMD programs and support dose escalation to drive a higher therapeutic index

ELEVATE-44-201

Cohort 1: Functional Efficacy Data

Cohort 1 achieved functional benefit via statistically significant measurements in both TTR and TTRV; 10MWR trending favorably with additional metrics to be shared by year-end 2026

- **Time to Rise and Time to Rise Velocity are the first functional measurements to “move”**
 - TTR improvement versus placebo = 2.40 seconds (statistically significant)
 - TTRV improvement versus placebo = 0.09 rises per second (statistically significant)
- **Functional benefit demonstrated via Time to Rise and Time to Rise Velocity measurements**
 - TTRV is a calculation based on TTR that minimizes any imputation, outliers and noise associated with TTR
 - TTRV is a clinically significant and accepted regulatory endpoint
 - Cohort 1 resulted in a statistically significant impact on TTRV versus placebo at levels several fold above MCID after only 3 doses (127 days, 6 weeks after the last dose administered)
 - TTR and TTRV generally precede improvements in other functional measures (10MWR, etc.)
- Positive trends observed in 10MWR and will be tracked and reported at the end of the open-label period (year-end 2026)
- Additional metrics (e.g., 4SC) to be reported at the end of the open-label period (year-end 2026)

Early functional benefit response is compelling and statistically significant

Functional improvement

The importance and meaning of Time to Rise velocity

Time to Rise, a secondary endpoint in this study, is a robust, prognostic factor that predicts disease progression; Time to Rise velocity reduces the impact of imputation, outliers and noise


- **TTR declines rapidly** over time in patients with DMD and is an early **prognostic factor for disease progression and loss of ambulation**¹
 - The largest absolute and proportional annual signal among functional measures and early prognostic factor for disease progression and loss of ambulation
 - Robust, as rising from the floor depends on proximal strength and postural control, functions affected early in disease progression¹
 - Precedes improvements in 4-stair climb or 10-meter walk test and less complicated than NSAA²
- **TTRV** is calculated as $1/TTR$, expressed as rises/second and is designed to reduce the impact of outliers and imputed data (illustration at right)
 - Handles the unable to perform problem by scoring that observation at zero avoiding arbitrary scoring
 - Dampens clinically meaningless scoring noise between visits
 - Compresses the long tail and produces a distribution that is much closer to normal, which matters for parametric statistics



Table 1. Clinical relevance of TTSTAND measurements¹

TTSTAND	Clinical relevance
<5 seconds	Suggests functional stability ^{2,3}
≥5 seconds	Indicates functional impairment ^{2,3} Shown to predict disease progression over 48 weeks ^{2,3}
≥10 seconds	Shown to predict risk of losing ambulation in the ensuing 2 years ³

Fig 1. Predicted probability of losing ability to stand at 24 months given baseline time to stand from supine assessment (TTSTAND). Adjustment made for baseline age and cumulative steroid use at baseline



Illustrative Data and Representative Calculation of TTRV

TTR baseline (seconds)	TTR end of study (seconds)	Improvement (seconds)	TTRV calculation	Δ TTRV (rises/sec)
6.0	3.89	2.11	$1/3.89 - 1/6.0 = 0.257 - 0.167$	+0.09
8.0	4.65	3.35	$1/4.65 - 1/8.0 = 0.215 - 0.125$	+0.09
10.0	5.26	4.74	$1/5.26 - 1/10.0 = 0.190 - 0.100$	+0.09

Explanation: A boy starting at a TTR of 6 seconds needs to improve by ~2 seconds to achieve +0.09 ΔTTRV, but a boy starting at a TTR of 10 seconds needs to improve by ~4.5 seconds for the same velocity change

Functional cascade: TTR velocity is a robust indicator of treatment effect and the earliest measurement to move

Proximal functional measures, including TTR and 4SC, detect changes before composite/distal measures like PUL and NSAA; TTR and TTRV were statistically significant versus placebo in Cohort 1

Relevant Study Period	Relevant Functional Readout	Status Of Functional Measure Collection and Readout
MAD (18 weeks)	TTR Velocity <i>Time to Rise</i> SV95C <i>Stride Velocity 95th Centile</i>	<ul style="list-style-type: none"> Statistically significant improvement versus placebo demonstrated in Cohort 1 MAD portion of the study Not collected during Cohort 1 MAD; To be reported at the end of the open-label period
Open-Label (~1 year)	10MWR Velocity <i>10-Meter Walk/Run</i> 4SC Velocity <i>4 Stair Climb</i>	<ul style="list-style-type: none"> Trend towards functional improvement in Cohort 1 MAD portion of the study; Will be assessed at the end of the open-label period Baseline not collected in Cohort 1 MAD; To be reported at the end of the open-label period
OL – LTE* (≥1 year)	NSAA <i>North Star Ambulatory</i> PUL 2.0 <i>Performance Upper Limb</i>	<ul style="list-style-type: none"> Composite measure; Will be assessed at the end of the open-label period Less sensitive in ambulatory participants; To be reported at the end of the open-label period


ENTR-601-44 Cohort 1 detected a statistically significant TTRV signal at Day 127 (18 weeks) which is consistent with TTRV being the earliest timed function test to detect treatment effect

Disease-modifying functional benefit seen at lowest dose

TTRV results

Significant improvements in TTR and TTRV were observed*; TTRV is a widely accepted Phase 3 endpoint in DMD, with good statistical properties for evaluating motor function in patients

TTRV Improvement Versus Placebo*



Key Takeaways

- **TTR is a pre-specified secondary endpoint in the ELEVATE-44-201 study**
- Change in TTR and in TTRV was seen across the majority of treated participants, irrespective of age
- The mean change in TTRV versus placebo was 0.09, ~3.5x higher than the MCID threshold of 0.023
- End of Cohort 1 dystrophin levels correlated with the end of Cohort 1 TTRV, suggesting that dystrophin production may have crossed a critical threshold for functional improvement
- The magnitude of the overall response supports the hypothesis that Cohort 1's functional benefit represents a true drug-related effect
- In addition, 10MWR also demonstrated positive trends versus placebo

*Analysis on TTRV versus placebo shown rather than TTR in order to maintain the study blind, Wilcoxon rank-sum (one sided) test, nominal p-values, post hoc analysis; MCID: "The Minimal Clinical Important Difference (MCID) in Annual Rate of Change of Timed Function Tests in Boys with DMD," Duong T, Canbek J, Birkmeier M, Nelson L, Siener C, Fernandez-Fernandez A, Henricson E, McDonald CM, Gordish-Dressman H and the CINRG-DNHS Investigators; Journal of Neuromuscular Diseases. 2021;8(6):939-948; Updated from previously disclosed topline data to reflect subsequently received information.


ENTR-601-44 delivered a differentiated impact on TTRV

TTRV is a validated registrational endpoint



ENTR-601-44's TTRV versus placebo is superior to reported numbers from steroids, gene therapy and second-generation exon skipping therapies

Reported TTRV Competitive Comparisons






- Phase 3 trials using TTRV as the primary endpoint: **Novartis:** *del-zota*, Phase 3 (initiating); **Dyne:** 251/Z-rostudirsen, Phase 3 (initiating) **Solid Biosciences:** SGT-003, Phase 3 (ongoing); **Roche:** Elevidys, Phase 3 (to initiate in EU)

Sources: *VISION-DMD (JAMA 2022) registrational study; DELIVER (Dyne Company presentation; June 2026); EMBARK (MDA 2026); ENTR-601-44 (Cohort 1); No head-to-head trials have been conducted; Cross-trial comparisons may not be reliable based on differences in study designs, compound formulation and mechanism, patient populations, etc.

ELEVATE-44-201: Pharmacokinetics and Biomarkers

Lower-than-expected plasma exposures resulted in lower-than-expected exon skipping and dystrophin expression

Lower C_{max} and AUC observed in pediatric participants when compared with healthy adults




A linear (or better) increase in exposure is expected in Cohort 2 at 12 mg/kg which should result in substantially higher dystrophin levels and continued muscle function

ENTR-601-44: Mechanistic Rationale

An ideal treatment is regenerative – replacing damaged, dystrophic muscle with healthy muscle; This requires satellite cell correction which then promotes asymmetric differentiation

Healthy muscle

- Dystrophin supports stabilizing and repairing muscle fibers and stem cell replenishment and function




The dystrophin “double hit” results in a decline in function

- Lack of dystrophin results in muscle damage
- Lack of dystrophin also results in the inability to repair and regenerate new fibers
- Lack of normal regeneration results in the replacement of muscle with fat and fibrosis

DMD muscle lacking dystrophin

- Muscle fibers susceptible to damage
- Stem cells and regeneration impaired
- Muscle replaced with fat and scar tissue



Satellite (stem) cells require dystrophin to efficiently promote muscle regeneration

- Deficit inhibits asymmetric differentiation and activation, thus impairing regeneration

EEV-enabled stem cell uptake implies the potential for the return of healthy muscle and function


Enhanced satellite cell activity would result in the regeneration of healthy fibers and the stabilization of the overall muscle; In turn, this may convert into greater strength, as measured by TTRV

Entrada differentiation

- Immunohistochemistry data demonstrates PMO in satellite cells and newly regenerated centrally nucleated fibers 12 weeks post-washout after 3 Q6W doses (D2-*mdx* mice)

Antibody and gene therapy competitors

- No transferrin receptor expressed on these cells so the antibodies cannot reach them
- AAV-enabled gene therapies lack ability to efficiently reach satellite cells which limits response durability



Immunohistochemistry data demonstrates PMO in satellite cells and newly regenerated centrally nucleated fibers 12-weeks post-washout after 3 Q6W doses (D2-*mdx* mice)

Myotonic Dystrophy Type 1 (DM1)

No disease-modifying treatments are currently available for the more than 110,000 people in the U.S. and Europe living with DM1

DM1 partnership established with Vertex in Q1 2023

- Entrada received an upfront payment of \$224M and an equity investment of \$26M upon initiation of the collaboration
- Agreement provided for up to \$485M for the achievement of milestones
- Tiered royalties on future net sales

VX-670 differentiation

- Unlike antibody-based approaches, VX-670's targeted and specific blocking of pathogenic CUG repeats drives global transcriptome correction while preserving healthy DMPK levels
- Satellite cell uptake may improve outcomes as CUG repeat length correlates with progenitor cell activation, proliferation and differentiation*

Vertex advancing a placebo-controlled Phase 1/2 clinical program at over 25 global sites

- MAD portion of the clinical study to assess safety and efficacy is on track to read out in the second half of 2026
- Open-label extension study is enrolling
- Same EEV utilized for VX-670 as in DMD franchise



Inherited Retinal Diseases (IRDs)

Addressing areas of high unmet need in IRDs with new oligonucleotide-based therapeutics


Entrada's first IRD clinical candidate, ENTR-801, will target Usher syndrome type 2A; Addressable population is ~15,000 patients* in the U.S. and Europe with no approved therapeutics

Usher Syndrome Type 2A (USH2A)

- An inherited eye condition caused by changes in the USH2A gene
- In some patients, mutations in exon 13 prevent production of the usherin protein
- Without usherin, photoreceptors (the light-sensing cells in the eye) gradually degenerate
- Lack of usherin leads to vision loss in early adulthood and legal blindness in mid-adulthood
- **No disease-modifying treatments are currently available that can slow or stop disease progression**

About ENTR-801

- Proprietary exon 13 skipping therapy designed to restore functional usherin protein production with the goal of preserving photoreceptor health and function
- Demonstrated robust exon skipping and usherin protein production, with the potential for quarterly dosing IVT
- IND-enabling studies will be initiated and clinical strategies will be shared in 2026
- **~15,000 patients in the U.S. and Europe are exon 13 skipping amenable***



2026 Inflection Points

ELEVATE-44-201 Cohort 1 open-label functional data, Cohort 2 safety, dystrophin and functional data and ELEVATE-45-201 Cohort 1 data represent additional 2026 catalysts

- **All ELEVATE-44-201 Cohort 1 participants have rolled over into the open-label portion of the study**
 - Placebo participants crossed over into treatment via the open-label period
 - Company expects continued functional response with additional measurements collected during open-label period
 - Completion of open-label period expected by year-end 2026
- **ELEVATE-44-201 Cohort 2 at 12 mg/kg continues to enroll with readout expected by year-end 2026**
 - Higher levels of plasma and muscle exposure expected
 - Concomitant increases in exon skipping and dystrophin production are expected
 - Continued functional responses expected at higher doses
- **ELEVATE-45-201 Cohort 1 at 5 mg/kg fully enrolled with readout expected in mid-2026**
 - Data Monitoring Committee cleared Cohort 2 dosing at 10 mg/kg and enrollment has initiated
 - Significant unmet market need for new therapies
 - ELEVATE-45-201 dosing regimen of every 6 weeks is a potentially compelling point of differentiation

Multiple 2026 near-term value drivers anticipated across expanding pipeline of intracellular therapeutics

ENTR-601-44

Global Phase 1/2 MAD study ongoing

Cohort 1 data demonstrated safety, dystrophin production and functional improvement

Cohort 2 data expected by year-end 2026

ENTR-601-45

Global Phase 1/2 MAD study ongoing

Cohort 1 data expected mid-2026

Cohort 2 cleared to dose escalate to 10 mg/kg and enrollment has initiated

ENTR-601-50

Received authorization for Phase 1/2 MAD study (U.K.)

EU regulatory filing expected following a review of data from the ongoing DMD clinical studies

ENTR-601-51

Global regulatory filings expected following a review of data from the ongoing DMD clinical studies

VX-670

Vertex is on track to share results in H2 2026

ENTR-801

Initial IRD candidate focused on Usher syndrome type 2A

Additional data and clinical plans will be shared in 2026

Second IRD candidate declaration in H2 2026

Pipeline Expansion

Next-generation EEVs for neuromuscular expansion

Ocular expansion into larger disease areas

Range of undisclosed diseases and modalities

Cash runway into Q3 2027*

Appendix


EEV™ Platform

Unique pH-dependent membrane binding affinity enhances EEV endosomal escape

- EEVs have a higher affinity to phospholipids compared to traditional linear CPPs; The interaction of EEVs with phospholipids is pH-dependent
- The specific interaction of EEVs with the endosomal membrane facilitates the escape of EEVs from early endosomes, as demonstrated by the correlation between endosomal escape efficiency and endosomal membrane binding affinity


Concept

Efficient Endosomal Escape
~25-50-fold increase in endosomal escape vs. other competitive approaches




Mechanism

Insertion of hydrophobic groups induces positive curvature
Binding of Arg-rich peptides induces negative curvature




Visualization



Entrada optimizes both the EEV delivery vehicle and the active conjugate to create best-in-class medicines


In the below DMD example, Entrada has optimized the EEV and the PMO sequence;
The data represents the superiority of each component against other approaches and sequences

EEV Optimization



- PMO sequences are the same, cell penetrating peptides are different (linear vs. cyclic)
- EEV-PMO significantly improved exon skipping after 3 days in *mdx* mice as compared to competitive R6-PMO

PMO Optimization




- EEVs are the same, PMO sequences are different (casimersen vs. Entrada proprietary)
- Proprietary PMO significantly improved exon skipping after 3 days in *mdx* mice as compared to competitive casimersen sequence

DMD Approach

Entrada addresses the underlying cause of DMD and restores dystrophin in muscle fibers and muscle stem cells

The Duchenne Disease Cascade



Current and Emerging Treatment Options

1. Disease-modifying agents address the root cause of morbidity and mortality

- Double-digit high-quality dystrophin production protects healthy muscle and restores regenerative capacity
- Must be safe, potent, reach both mature and progenitor cells, be infrequently dosed, be redosable and dosing is weight based to meet the needs of a growing child
- **Entrada is developing the only disease-modifying agents with the potential to meet ALL of the above¹**

2. Supportive care agents only address downstream biology

- Myosin(i), AAK1(i), HDAC(i) may potentially enhance disease-modifying therapies and complement dystrophin restoration
- Mechanisms include membrane protection/repair and stem cell proliferation
- Symptomatic care, led by steroids, have served as standard of care despite long-term tolerability and safety concerns

Entrada's next-generation exon skippers

- Established safety at a therapeutic dose of 6 mg/kg with escalation to 12 mg/kg underway²
- Expected to provide durable and significant access to skeletal and cardiac muscle
- Target progenitor cells (satellite) needed to regenerate muscle and provide functional benefit
- Flexible to dose escalate and redose

Competitive Comparison

EEV therapies are expected to show superior dystrophin production and dose-dependent increases in therapeutic index



A 25-50-fold improvement in endosomal escape, novel PMO sequences, non-linear increases in PK/PD, satellite cell uptake and lower whole drug requirements compared to antibody-based therapies

EEV-PMO Entrada

Cyclic, arginine-light peptide
2.6 kDa

Tissue-specific delivery; Increases stability and half-life

Anti-TfR1-mAb-PMO (exon 44) Novartis/Avidity

Full-length antibody
~150 kDa

TfR1 specific deliver; Non-cleavable linker

Anti-TfR1-Fab-PMO (exon 51) Dyne

Fragment antibody
~50 kDa

TfR1 specific delivery; Cleavable linker

Design

Dose

Uptake

Target engagement

Low conjugate doses

✓ ~5 mg/kg PMO + 1 mg/kg EEV = **6 mg/kg whole drug (ELEVATE-44-201 Cohort 1 dose)**

Large conjugate doses

– 5 mg/kg PMO (registrational dose) + ~23 mg/kg mAb = **~28 mg/kg whole drug dose¹**

Large conjugate doses

– 20 mg/kg PMO (registrational dose) + undisclosed mg/kg Fab = **undisclosed mg/kg whole drug dose²**

No limit on dose response seen

✓ **48.3%** increase in exon skipping from 3 to 6 mg/kg whole drug dose in HNV³

Apparent limit on dose response

– No increase in dystrophin from 5 to 10 mg/kg PMO dose in DMD exon 44 patients: **25% vs. 26%^{4,5}**

Apparent limit on dose response

– No increase in dystrophin from 10 to 20 mg/kg PMO dose in DMD exon 51 patients: **2.97% vs. 3.14%^{2,4}**

Enhanced endosomal escape

✓ **~25-fold increase in endosomal escape vs. other competitive approaches**

No enhanced endosomal escape

– Once dissociated from the mAb in the lysosome, the unconjugated PMO escapes at **<2% efficiency⁶**

No enhanced endosomal escape

– Once dissociated from the Fab in the endosome, the unconjugated PMO escapes at **<2% efficiency⁶**



TfR1: Transferrin receptor 1; ¹Etzaniz et al., Nucleic Acid Res., 2025; ²Dyne corporate materials from DELIVER Clinical Update investor call September 2025; ³Total mean exon skipping; Entrada internal data from Phase 1 SAD study of ENTR-601-44 in HNV; ⁴Unadjusted dystrophin, mean change from baseline; ⁵Avidity corporate materials from del-zota Topline Data investor call March 2025; ⁶Dowdy et al., Nucleic Acid Ther., 2022.

Pharmacokinetic Modeling

Lower C_{max} and AUC observed in juvenile humans and NHPs; A linear (or better) increase in exposure is expected in Cohort 2 at 12 mg/kg (double dose = double exposure)

Human (HNVs and Patients)*

Non-Human Primate**




Improved, predictive modeling based on new data point to higher dystrophin levels in Cohorts 2 and 3

Juvenile NHP data suggest an increase of AUC should result in substantially higher dystrophin levels and increases in muscle function

- Juvenile NHP data suggest a right-shifted double-digit dystrophin expectation starting at 12 mg/kg in Cohort 2
- As the exposure to exon skipping relationship has not changed, updated projections indicate significantly increased exon skipping and dystrophin expression expected in Cohorts 2 and 3
- Cohorts 2 and 3 dystrophin levels will be assessed for registrational potential, when combined with observed functional outcomes

Juvenile NHP Plasma Concentration and Exon Skipping




DMD Functional Data

Preclinical Models

Preclinical data support potential for best-in-class clinical profile for ENTR-601-45

Dose-dependent increase in exon skipping and dystrophin expression correlates to complete functional correction





- Active and vehicle del44hDMD.mdx mice, n=5 per cohort, EEV-PMO-45 (Q6W x 3 doses); Control saline treated hDMD.mdx mice, n=10 (Q6W x 3 doses)
- Skipping (ddPCR) and dystrophin production (JESS) is significantly increased 6 weeks after the third dose of ENTR-601-45 (gastrocnemius muscle shown)

Dose-dependent and durable improvements in muscle function observed in del44hDMD.*mdx* mice


ENTR-601-45

Dose-dependent increase in percent force retention following 10 contractions; Increase maintained for at least 8 weeks after the third Q6W dose of ENTR-601-45

Skeletal Muscle Membrane Stability




Stability After Washout




del44hDMD.*mdx* mice were treated with three Q6W IV injections of ENTR-601-45 or vehicle; ECC-induced muscle force loss generated by repeated eccentric force (ECC) contraction of the gastrocnemius muscle was assessed 5 weeks (left/center) or 4 and 8 weeks (right) after the third dose; Data (mean ± standard deviation) shown across 10 ECC contractions normalized into a percentage of the initial force before any ECC contractions and as the percentage of force retained after the tenth contraction; Vehicle-treated hDMD.*mdx* mice were used as a control group for normal muscle function; One-way ANOVA (Analysis of variance) was used for statistical comparison to vehicle-treated del44hDMD.*mdx* mice; **p < 0.01, ***p < 0.001, ****p < 0.0001 vs. vehicle; Data presented at the 2024 World Muscle Society conference.

Single dose of ENTR-601-50 produced robust human *DMD* exon 50 skipping and dystrophin; Translated into improvements in muscle function within 2 weeks post-dose

Exon Skipping and Dystrophin in the Gastrocnemius




- del51hDMD.mdx mice
- del51hDMD.mdx vehicle
- 25 mg/kg ENTR-601-50
- 45 mg/kg ENTR-601-50



- del51hDMD.mdx mice
- del51hDMD.mdx vehicle
- 25 mg/kg ENTR-601-50
- 45 mg/kg ENTR-601-50

Percent Force After 10 Contractions



** $p \leq 0.01$, **** $p \leq 0.0001$, **** $p \leq 0.0001$ vs. Vehicle



Learn more at
EntradaTx.com

 **entrada**
THERAPEUTICS